Research Analysts Set Expectations for Sanofi Q2 Earnings
Zacks Research cut their Q2 2025 EPS estimates for shares of Sanofi in a research report issued on Wednesday, February 19th.
Sanofi (SNY): Among the Cheap Pharmaceutical Stocks to Buy According to Analysts
We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...
Nasdaq26d
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
Sanofi SNY reported fourth-quarter 2024 adjusted earnings of 70 cents per American depositary share, which missed the Zacks Consensus Estimate of 71 cents per share. Earnings of €1.31 per share ...
Nasdaq7d
Regeneron & Sanofi : FDA Accepts Dupixent SBLA For Priority Review In Bullous Pemphigoid Treatment
Dupilumab is being jointly developed by Regeneron and Sanofi under a global collaboration ... author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew ...
Nasdaq6d
Sanofi Signs Share Purchase Deal To Sell 50% Controlling Stake In Opella To CD&R
Sanofi now said the agreement follows completion ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq22d
Agreement Between L’Oréal and Sanofi for the Repurchase by Sanofi of 2.3% of Its Own Shares Held by L’Oréal
AGREEMENT BETWEEN L’ORÉAL AND SANOFI FOR THE REPURCHASEBY SANOFI OF 2.3% OF ITS OWN SHARES HELD BY L’ORÉAL Clichy, February 3, 2025 – L’Oréal announces today that it has agreed to sell ...
Nasdaq22d
Sanofi Announces Buy Back Of Shares From L'Oréal - Quick Facts
Sanofi said the acquisition of these shares ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York, with ...
Nasdaq7d
Regeneron and Sanofi Announce FDA Priority Review for Dupixent® as Potential First Targeted Treatment for Bullous Pemphigoid
Inc. (NASDAQ: REGN) and Sanofi today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Dupixent ...
Nasdaq26d
Sanofi: Information concerning the total number of voting rights and shares - December 2024
Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlem ...
Sanofi/Teva Unveil New Detailed Data For Duvakitug Study Supporting Overall Efficacy For Common Inflammatory Bowel Disease
Teva Pharmaceuticals Industries Ltd. (NYSE:TEVA) and Sanofi SA (NASDAQ:SNY) presented new, detailed results from the RELIEVE ...
Nasdaq26d
Sanofi Q4 Business Net Income Declines; Net Sales Up 10.3% At CER
Sanofi confirmed the expectation of a strong ... and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in the late 1990s by Andrew Mariathasan in New York ...
Nasdaq7d
Dupixent® (dupilumab) sBLA Accepted for FDA Priority Review for the Targeted Treatment of Bullous Pemphigoid (BP)
Sanofi is listed on EURONEXT: SAN and NASDAQ: SNY. All trademarks mentioned in this press release are the property of the Sanofi group except for VelociSuite and Regeneron Genetics Center.